TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 174,800 shares, a growth of 71.4% from the February 29th total of 102,000 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 619,400 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of TransCode Therapeutics

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of TransCode Therapeutics in the 2nd quarter worth $25,000. UBS Group AG bought a new stake in TransCode Therapeutics in the 3rd quarter valued at $74,000. Sabby Management LLC boosted its position in shares of TransCode Therapeutics by 32.8% during the third quarter. Sabby Management LLC now owns 250,309 shares of the company’s stock worth $126,000 after buying an additional 61,872 shares during the period. Citadel Advisors LLC acquired a new position in TransCode Therapeutics during the 4th quarter worth approximately $46,000. Finally, Worth Venture Partners LLC boosted its holdings in TransCode Therapeutics by 9.7% during the first quarter. Worth Venture Partners LLC now owns 324,157 shares of the company’s stock worth $934,000 after purchasing an additional 28,617 shares during the last quarter.

TransCode Therapeutics Price Performance

Shares of RNAZ remained flat at $0.68 during mid-day trading on Thursday. The stock had a trading volume of 248,159 shares, compared to its average volume of 664,147. The stock’s fifty day moving average price is $0.70 and its 200-day moving average price is $9.61. The stock has a market cap of $426,132.00, a P/E ratio of 0.00 and a beta of -0.38. TransCode Therapeutics has a fifty-two week low of $0.56 and a fifty-two week high of $392.00.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.